In Philadelphia chromosome-positive ALL, tyrosine kinase inhibitor (dasatinib and ponatinib) can upregulate BIM and inhibit the expression of MCL1, thereby cooperating with venetoclax to inhibit ALL cells [65]. This evidence concerns the gene MCL1 and acute lymphoblastic leukemia.